ZEPHYRx and NIOX announced they have partnered to integrate FeNO by NIOX into the ZEPHYRx Respiratory Cloud Platform to advance clinical research by offering one source of truth for multiple respiratory endpoints. In working with sponsors, ZEPHYRx and NIOX recognized a need for a more seamless solution by integrating FeNO by NIOX measurements into the ZEPHYRx platform. NIOX is the partner of choice for ZEPHYRx to further expand its offering for clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.6 GBX | -1.48% | +3.10% | -0.60% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.60% | 352M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- CIR Stock
- News NIOX Group Plc
- ZEPHYRx and NIOX Announce to Work Together to Advance Respiratory Clinical Research